Ultragenyx Pharmaceutical reported $59M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Insmed USD 163.95M 21.56M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Kyowa Hakko Kirin JPY 65.24B 2.2B Mar/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Moderna USD 313M 33M Sep/2026
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026